Synthesis and evaluation of novel xanthene-based thiazoles as potential antidiabetic agents. 2023

Saira Naseem, and Zahid Shafiq, and Parham Taslimi, and Saghir Hussain, and Tugba Taskin-Tok, and Dursun Kisa, and Aamer Saeed, and Ahmed Temirak, and Muhammad N Tahir, and Khawar Rauf, and Ahmed El-Gokha
Institute of Chemical Sciences, Bahauddin Zakariya University, Multan, Pakistan.

A series of xanthene-based thiazoles was synthesized and characterized by different scpectroscopic methods, i.e. Proton nuclear magnetic resonance (1 H NMR), carbon nuclear magnetic resonance (13 C NMR), infrared spectroscopy, carbon hydrogen nitrogen analysis, and X-ray crystallography. The inhibition potencies of 18 newly synthesized thiazole derivatives were investigated on the activities of acetylcholinesterase (AChE), butyrylcholinesterase (BChE), α-amylase (α-Amy), and α-glycosidase (α-Gly) enzymes in accordance with their antidiabetic and anticholinesterase ability. The synthesized compounds have the highest inhibition potential against the enzymes at low nanomolar concentrations. Among the 18 newly synthesized molecules, 3b and 3p were superior to the known commercial inhibitors of the enzymes and have a much more effective inhibitory potential, with IC50 : 2.37 and 1.07 nM for AChE, 0.98 and 0.59 nM for BChE, 56.47 and 61.34 nM for α-Gly, and 152.48 and 124.84 nM for α-Amy, respectively. Finally, the optimized 18 compounds were subjected to molecular docking to describe the interaction between thiazole derivatives and AChE, BChE, α-Amy, and α-Gly enzymes in which important interactions were monitored with amino acid residues of each target enzyme.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D002091 Butyrylcholinesterase An aspect of cholinesterase (EC 3.1.1.8). Pseudocholinesterase,Benzoylcholinesterase,Butyrylthiocholinesterase
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D006026 Glycoside Hydrolases Any member of the class of enzymes that catalyze the cleavage of the glycosidic linkage of glycosides and the addition of water to the resulting molecules. Endoglycosidase,Exoglycosidase,Glycohydrolase,Glycosidase,Glycosidases,Glycoside Hydrolase,Endoglycosidases,Exoglycosidases,Glycohydrolases,Hydrolase, Glycoside,Hydrolases, Glycoside
D000110 Acetylcholinesterase An enzyme that catalyzes the hydrolysis of ACETYLCHOLINE to CHOLINE and acetate. In the CNS, this enzyme plays a role in the function of peripheral neuromuscular junctions. EC 3.1.1.7. Acetylcholine Hydrolase,Acetylthiocholinesterase,Hydrolase, Acetylcholine
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013844 Thiazoles Heterocyclic compounds where the ring system is composed of three CARBON atoms, a SULFUR and NITROGEN atoms. Thiazole
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking

Related Publications

Saira Naseem, and Zahid Shafiq, and Parham Taslimi, and Saghir Hussain, and Tugba Taskin-Tok, and Dursun Kisa, and Aamer Saeed, and Ahmed Temirak, and Muhammad N Tahir, and Khawar Rauf, and Ahmed El-Gokha
March 2014, Chemical biology & drug design,
Saira Naseem, and Zahid Shafiq, and Parham Taslimi, and Saghir Hussain, and Tugba Taskin-Tok, and Dursun Kisa, and Aamer Saeed, and Ahmed Temirak, and Muhammad N Tahir, and Khawar Rauf, and Ahmed El-Gokha
January 2020, Drug design, development and therapy,
Saira Naseem, and Zahid Shafiq, and Parham Taslimi, and Saghir Hussain, and Tugba Taskin-Tok, and Dursun Kisa, and Aamer Saeed, and Ahmed Temirak, and Muhammad N Tahir, and Khawar Rauf, and Ahmed El-Gokha
June 2020, Future medicinal chemistry,
Saira Naseem, and Zahid Shafiq, and Parham Taslimi, and Saghir Hussain, and Tugba Taskin-Tok, and Dursun Kisa, and Aamer Saeed, and Ahmed Temirak, and Muhammad N Tahir, and Khawar Rauf, and Ahmed El-Gokha
November 2015, Chemical biology & drug design,
Saira Naseem, and Zahid Shafiq, and Parham Taslimi, and Saghir Hussain, and Tugba Taskin-Tok, and Dursun Kisa, and Aamer Saeed, and Ahmed Temirak, and Muhammad N Tahir, and Khawar Rauf, and Ahmed El-Gokha
April 2023, Future medicinal chemistry,
Saira Naseem, and Zahid Shafiq, and Parham Taslimi, and Saghir Hussain, and Tugba Taskin-Tok, and Dursun Kisa, and Aamer Saeed, and Ahmed Temirak, and Muhammad N Tahir, and Khawar Rauf, and Ahmed El-Gokha
February 2024, RSC advances,
Saira Naseem, and Zahid Shafiq, and Parham Taslimi, and Saghir Hussain, and Tugba Taskin-Tok, and Dursun Kisa, and Aamer Saeed, and Ahmed Temirak, and Muhammad N Tahir, and Khawar Rauf, and Ahmed El-Gokha
October 2007, European journal of medicinal chemistry,
Saira Naseem, and Zahid Shafiq, and Parham Taslimi, and Saghir Hussain, and Tugba Taskin-Tok, and Dursun Kisa, and Aamer Saeed, and Ahmed Temirak, and Muhammad N Tahir, and Khawar Rauf, and Ahmed El-Gokha
January 2011, European journal of medicinal chemistry,
Saira Naseem, and Zahid Shafiq, and Parham Taslimi, and Saghir Hussain, and Tugba Taskin-Tok, and Dursun Kisa, and Aamer Saeed, and Ahmed Temirak, and Muhammad N Tahir, and Khawar Rauf, and Ahmed El-Gokha
January 2023, Future medicinal chemistry,
Saira Naseem, and Zahid Shafiq, and Parham Taslimi, and Saghir Hussain, and Tugba Taskin-Tok, and Dursun Kisa, and Aamer Saeed, and Ahmed Temirak, and Muhammad N Tahir, and Khawar Rauf, and Ahmed El-Gokha
January 2014, PloS one,
Copied contents to your clipboard!